Overview

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2006-05-30
Target enrollment:
Participant gender:
Summary
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany